<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633591</url>
  </required_header>
  <id_info>
    <org_study_id>TOLC101MR</org_study_id>
    <secondary_id>2017-003070-13</secondary_id>
    <nct_id>NCT03633591</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone</brief_title>
  <official_title>A Phase 1, Single-Part, 6-Period, Sequential, Non-Randomized, Open-Label Study Designed to Evaluate the Pharmacokinetic Profile of Tolcapone Following Administration of Modified Release Prototype Formulations and an Experimental Divided Dose Regimen in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corino Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corino Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic profiles of tolcapone in healthy
      subjects after administration of one or two oral doses of multiple modified release prototype
      formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">October 22, 2018</completion_date>
  <primary_completion_date type="Actual">October 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment: Time to maximum concentration (Tmax)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment: Maximum observed concentration (Cmax)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment: Area under the curve (AUC)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment: Plasma half-life (t1/2)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Plasma half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment: Relative bioavailability (Frel)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Relative bioavailability (Frel)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment of 3-O-Methyltolcapone: Time to maximum concentration (Tmax)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment of 3-O-Methyltolcapone: Maximum observed concentration (Cmax)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment of 3-O-Methyltolcapone: Area under the curve (AUC)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment of 3-O-Methyltolcapone: Plasma half-life (t1/2)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Plasma half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment of 3-O-Methyltolcapone: Relative Bioavailability (Frel)</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <description>Relative Bioavailability (Frel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting treatment-related Adverse Events (AEs)</measure>
    <time_frame>Screening to 10 days following last dose</time_frame>
    <description>Abnormalities in safety laboratory tests, vital signs, electrocardiogram, physical examination that meet the protocol definition will be captured as AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Modified Release Prototypes of Tolcapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>Multiple doses of tolcapone tablets in the fasted state</description>
    <arm_group_label>Modified Release Prototypes of Tolcapone</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone Modified Release Prototype</intervention_name>
    <description>A single dose of tolcapone modified release prototype in the fasted state</description>
    <arm_group_label>Modified Release Prototypes of Tolcapone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone Divided Dose</intervention_name>
    <description>Tolcapone (suspension) in equal divided doses in the fasted state</description>
    <arm_group_label>Modified Release Prototypes of Tolcapone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone Modified Release Prototype</intervention_name>
    <description>A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)</description>
    <arm_group_label>Modified Release Prototypes of Tolcapone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or non-pregnant, non-lactating healthy females

          -  Age 18 to 65 years of age at the time of signing informed consent

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2 or, if outside the range, considered not
             clinically significant by the investigator

          -  Must be willing and able to communicate and participate in the whole study

          -  Must provide written informed consent

          -  Must agree to use an adequate method of contraception

        Exclusion Criteria:

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months prior to first dose.

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee.

          -  Subjects who have previously been enrolled in this study.

          -  History of any drug or alcohol abuse in the past 2 years.

          -  Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening

          -  Current users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 12 months

          -  Females of childbearing potential who are pregnant or lactating

          -  Subjects who do not have suitable veins for multiple venepunctures / cannulation as
             assessed by the investigator at screening

          -  Clinically significant abnormal biochemistry, hematology or urinalysis as judged by
             the investigator

          -  Hemoglobin below the lower limit of normal

          -  ALT or AST outside the normal reference range at screening or admission.

          -  Confirmed positive drugs of abuse test result

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  History of clinically significant cardiovascular, neurological, renal, hepatic,
             chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by
             the investigator

          -  Subjects with a history of cholecystectomy or gall stones

          -  Serious adverse reaction or serious hypersensitivity to any drug, the formulation
             excipients, or lactose intolerance

          -  Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator.

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedies in the 14 days before IMP administration.

          -  Contraindication for Tasmar®

          -  Failure to satisfy the investigator of fitness to participate for any other reason

        NOTE: Other inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litza McKenzie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

